keyword
MENU ▼
Read by QxMD icon Read
search

biliary tract carcinoma

keyword
https://www.readbyqxmd.com/read/28503556/therapeutic-options-for-intrahepatic-cholangiocarcinoma
#1
REVIEW
Manojkumar Bupathi, Daniel H Ahn, Tanios Bekaii-Saab
Biliary tract cancer (BTC) is a heterogeneous group of cancers, which is composed of intrahepatic cholangiocarcinoma (ICCA), extrahepatic cholangiocarcinoma (ECCA), gallbladder cancers and ampullary carcinomas. While all anatomic subgroups are treated uniformly, our understanding about the pathogenesis has allowed us to reason that each group represents a clinically and genetically diverse disease. The majority of patients present with locally advanced or metastatic disease, where the standard treatment is combination systemic cytotoxic chemotherapy with gemcitabine and cisplatin...
April 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28503555/surgical-options-for-intrahepatic-cholangiocarcinoma
#2
REVIEW
Kui Wang, Han Zhang, Yong Xia, Jian Liu, Feng Shen
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer, accounting for 10-15% of primary hepatic malignancy. The incidence and cancer-related mortality of ICC continue to increase worldwide. At present, hepatectomy is still the most effective treatment for ICC patients to achieve long-term survival, although its overall efficacy may not be as good as that for patients with hepatocellular carcinoma (HCC) due to the unique pathogenesis and clinical-pathological profiles of ICC. Viral infection, lithiasis and metabolic factors may all be associated with the pathogenesis of ICC...
April 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28480071/targeted-therapy-in-biliary-tract-cancers-current-limitations-and-potentials-in-the-future
#3
REVIEW
Selley Sahu, Weijing Sun
Biliary tract cancers (BTC)/Cholangiocarcinoma (CCA) is an aggressive biliary tract epithelial malignancy from varying locations within the biliary tree with cholangiocyte depreciation., including intrahepatic cholangiocarcinoma (iCCA) (iCCA), extrahepatic cholangiocarcinoma (eCCA) and gallbladder carcinoma (GBC). The disease is largely heterogeneous in etiology, epidemiology, and molecular profile. There are limited treatment options and low survival rates for those patients with advanced or metastatic disease...
April 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28480069/adjuvant-therapy-in-biliary-tract-and-gall-bladder-carcinomas-a-review
#4
REVIEW
Roshan S Prabhu, Jimmy Hwang
Biliary tract carcinomas are relatively rare, but are increasingly diagnosed. They comprise several anatomically contiguous sites, so are often grouped together, but they do appear to represent distinct diseases, in part because of anatomical and surgical considerations. Complete upfront surgical resection is generally difficult because these cancers are often diagnosed at relatively advanced stages of disease. Thus, adjuvant therapy is often considered. This paper will review the evidence underpinning current recommendations for adjuvant therapy in biliary carcinomas...
April 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28428144/association-of-aflatoxin-and-gallbladder-cancer
#5
Jill Koshiol, Yu-Tang Gao, Michael Dean, Patricia Egner, Chirag Nepal, Kristine Jones, Bingsheng Wang, Asif Rashid, Wen Luo, Alison Van Dyke, Catterina Ferreccio, Michael Malasky, Ming-Chang Shen, Bin Zhu, Jesper B Andersen, Allan Hildesheim, Ann W Hsing, John Groopman
BACKGROUND & AIMS: Aflatoxin, which causes hepatocellular carcinoma, may also cause gallbladder cancer. We investigated whether patients with gallbladder cancer have higher exposure to aflatoxin than patients with gallstones. METHODS: We measured aflatoxin B1 (AFB1)-lysine adducts in plasma samples from the Shanghai Biliary Tract Cancer case-control study, conducted from 1997 through 2001. We calculated age- and sex-adjusted odds ratios (ORs) and 95% CIs and the population-attributable fraction for 209 patients with gallbladder cancer and gallstones vs 250 patients with gallstones without cancer (controls)...
April 17, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28408243/erlotinib-and-bevacizumab-in-patients-with-advanced-non-small-cell-lung-cancer-and-activating-egfr-mutations-belief-an-international-multicentre-single-arm-phase-2-trial
#6
Rafael Rosell, Urania Dafni, Enriqueta Felip, Alessandra Curioni-Fontecedro, Oliver Gautschi, Solange Peters, Bartomeu Massutí, Ramon Palmero, Santiago Ponce Aix, Enric Carcereny, Martin Früh, Miklos Pless, Sanjay Popat, Athanasios Kotsakis, Sinead Cuffe, Paolo Bidoli, Adolfo Favaretto, Patrizia Froesch, Noemí Reguart, Javier Puente, Linda Coate, Fabrice Barlesi, Daniel Rauch, Michael Thomas, Carlos Camps, Jose Gómez-Codina, Margarita Majem, Rut Porta, Riyaz Shah, Emer Hanrahan, Roswitha Kammler, Barbara Ruepp, Manuela Rabaglio, Marie Kassapian, Niki Karachaliou, Rachel Tam, David S Shames, Miguel A Molina-Vila, Rolf A Stahel
BACKGROUND: The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the T790M resistance mutation with another EGFR mutation in treatment-naive patients has been associated with a shorter progression-free survival to EGFR inhibition than in the absence of the T790M mutation. To test this hypothesis clinically, we developed a proof-of-concept study, in which patients with EGFR-mutant NSCLC were treated with the combination of erlotinib and bevacizumab, stratified by the presence of the pretreatment T790M mutation...
May 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28375170/serum-metabolomic-profiles-for-human-pancreatic-cancer-discrimination
#7
Takao Itoi, Masahiro Sugimoto, Junko Umeda, Atsushi Sofuni, Takayoshi Tsuchiya, Shujiro Tsuji, Reina Tanaka, Ryosuke Tonozuka, Mitsuyoshi Honjo, Fuminori Moriyasu, Kazuhiko Kasuya, Yuichi Nagakawa, Yuta Abe, Kimihiro Takano, Shigeyuki Kawachi, Motohide Shimazu, Tomoyoshi Soga, Masaru Tomita, Makoto Sunamura
This study evaluated the clinical use of serum metabolomics to discriminate malignant cancers including pancreatic cancer (PC) from malignant diseases, such as biliary tract cancer (BTC), intraductal papillary mucinous carcinoma (IPMC), and various benign pancreaticobiliary diseases. Capillary electrophoresismass spectrometry was used to analyze charged metabolites. We repeatedly analyzed serum samples (n = 41) of different storage durations to identify metabolites showing high quantitative reproducibility, and subsequently analyzed all samples (n = 140)...
April 4, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28373474/evaluation-of-tumor-markers-and-their-impact-on-prognosis-in-gallbladder-bile-duct-and-cholangiocellular-carcinomas-a-pilot-study
#8
Vaclav Liska, Vladislav Treska, Tomas Skalicky, Jakub Fichtl, Jan Bruha, Ondrej Vycital, Ondrej Topolcan, Richard Palek, Jachym Rosendorf, Jiri Polivka, Lubos Holubec
BACKGROUND/AIM: The behavior of tumor markers in biliary tract malignancies is not well-known and has been scarcely studied. Such markers could play important roles in diagnostic and prognostic schemes as well as in decision-making about the best treatment strategies. This study analyzed the preoperative serum levels of conventional tumor markers (AFP, CEA, CA 19-9, CA 72-4), proliferative marker thymidine kinase (TK) and cytokeratins (TPA, TPS and CYFRA 21.1) in patients with gallbladder carcinoma, bile duct carcinoma (Klatskin) and cholangiocellular carcinoma, in relation to the patient prognosis...
April 2017: Anticancer Research
https://www.readbyqxmd.com/read/28350976/neuroendocrine-tumor-of-the-common-bile-duct-case-report
#9
C Raspanti, N Falco, V Silvestri, G Rotolo, S Bonventre, G Gulotta
Neuroendocrine tumors (NET) are a very heterogeneous group of neoplasms; in recent years we have seen an increase in their incidence (3.65 /100.000/year). They can be associated with hereditary endocrine syndromes (MEN, Von Hippel Lindau); they can occur at any age and the incidence is slightly higher in men than women. The aetiology of the neuroendocrine tumors is unclear; in most cases, inflammation of the bile ducts may be the underlying cause and for this reason, the initial patient's evaluation should be focused on the different aspects concerning the oncological one and the possible sequelae of the biliary obstructions that can evolve in biliary sepsis...
November 2016: Il Giornale di Chirurgia
https://www.readbyqxmd.com/read/28348580/outcome-and-genetic-factors-in-igg4-associated-autoimmune-pancreatitis-and-cholangitis-a-single-center-experience
#10
Matthias Buechter, Paul Manka, Falko Markus Heinemann, Monika Lindemann, Benjamin Juntermanns, Ali Canbay, Guido Gerken, Alisan Kahraman
Introduction. Most investigations on autoimmune pancreatitis (AIP) were published on Asian cohorts while those on Caucasians are limited. However, there might be differences related to the origin. Patients and Methods. We analyzed 36 patients and compared type 1 (AIP1) with type 2 (AIP2). Results. The majority of patients suffered from AIP1 (55.6%). AIP1 patients were significantly older than AIP2 patients (54.4 versus 40.8 years). Moreover, 85.0% of AIP1 patients had concurrent autoimmune cholangitis (AIC) while 18...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/28337739/intraductal-neoplasms-of-the-bile-duct-a-new-challenge-to-biliary-tract-tumor-pathology
#11
REVIEW
Yasuni Nakanuma, Katsuhiko Uesaka, Shiro Miyayama, Hiroshi Yamaguchi, Masayuki Ohtsuka
Invasive biliary tract carcinomas are usually tubular adenocaricnomas with abundant desmoplastic reactions and frequent ductal and periductal invasion at the time of the diagnosis. Recently, several intraductal neoplasms of the bile duct, particularly at a pre-invasive stage, have been recognized. They include intraductal papillary neoplasm of the bile duct (IPNB), biliary intraepithelial neoplasm (BilIN), and others, such as intraductal tubulopapillary neoplasm (ITPN) of the bile duct. IPNBs are grossly visible predominantly intraductal-growing papillary neoplasms covered by well-differentiated neoplastic epithelium with fine fibrovascular cores in the dilated bile ducts...
March 24, 2017: Histology and Histopathology
https://www.readbyqxmd.com/read/28314252/clinical-target-volume-in-biliary-carcinoma-a-systematic-review-of-pathological-studies
#12
REVIEW
Ilaria Marinelli, Alessandra Guido, Lorenzo Fuccio, Andrea Farioli, Valeria Panni, Lucia Giaccherini, Alessandra Arcelli, Giorgio Ercolani, Giovanni Brandi, Silvia Cammelli, Andrea Galuppi, Gabriella Macchia, Rezarta Frakulli, Gian C Mattiucci, Francesco Cellini, Milly Buwenge, Matteo Renzulli, Francesco Deodato, Savino Cilla, Vincenzo Valentini, Vincenzo Tombolini, Rita Golfieri, Alessio G Morganti
BACKGROUND/AIM: Radiotherapy is a treatment option for both adjuvant and neo-adjuvant settings for biliary tract cancer. Guidelines on the delineation of the target volume of lymph nodes are lacking; only generic indications are available, without specific recommendations for different primary tumour locations (e.g. intrahepatic, extrahepatic biliary tract or gallbladder cancer). The aim of this study was to systematically review available literature to provide recommendations on lymph node target volume delineation in patients with unresectable biliary tumour...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28292628/the-role-of-minimally-invasive-surgery-in-the-treatment-of-cholangiocarcinoma
#13
REVIEW
G B Levi Sandri, G Spoletini, G Mascianà, M Colasanti, P Lepiane, G Vennarecci, V D'Andrea, G M Ettorre
Cholangiocarcinoma (CC) is the second most common type of primary liver cancer after hepatocellular carcinoma. Surgical resection is considered the only curative treatment for CC. In general, laparoscopic liver surgery (LLS) is associated with improved short-term outcomes without compromising the long-term oncological outcome. However, the role of LLS in the treatment of CC is not yet well established. In addition, CC may arise in any tract of the biliary tree, thus requiring different types of treatment, including pancreatectomies and extrahepatic bile duct resections...
March 3, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28216138/clinicopathologic-characteristics-of-young-patients-with-gallbladder-cancer
#14
Sung-Im Do, Hyoun Wook Lee, Jin Hee Sohn, Kyungeun Kim
Gallbladder cancer is the most common biliary tract cancer and the fifth most common cancer of the digestive system. However, the clinicopathologic features of gallbladder cancer in young Korean patients have not been studied. This study included 101 consecutive cases of gallbladder cancer that underwent cholecystectomy at Kangbuk Samsung Hospital from December 1990 to March 2011. The patients were divided into two groups by age at initial diagnosis of gallbladder cancer: a young patient group aged less than 45 years and an old patient group aged 45 or older...
March 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28188502/efficacy-of-preoperative-portal-vein-embolization-among-patients-with-hepatocellular-carcinoma-biliary-tract-cancer-and-colorectal-liver-metastases-a-comparative-study-based-on-single-center-experience-of-319-cases
#15
Suguru Yamashita, Yoshihiro Sakamoto, Satoshi Yamamoto, Nobuyuki Takemura, Kiyohiko Omichi, Hiroji Shinkawa, Kazuhiro Mori, Junichi Kaneko, Nobuhisa Akamatsu, Junichi Arita, Kiyoshi Hasegawa, Norihiro Kokudo
BACKGROUND: Efficacy of preoperative portal vein embolization (PVE) has been established; however, differences of outcomes among diseases, including hepatocellular carcinoma (HCC), biliary tract cancer (BTC), and colorectal liver metastases (CLM), are unclear. METHODS: Subjects included patients in a prospectively collected database undergoing PVE (from 1995 to 2013). A future liver remnant (FLR) volume ≥40% is the minimal requirement for patients with an indocyanine green retention rate at 15 min (ICGR15) <10%, and stricter criteria (FLR volume ≥50%) have been applied for patients with 20% > ICGR15 ≥ 10%...
February 10, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28152549/circulating-copper-and-zinc-levels-and-risk-of-hepatobiliary-cancers-in-europeans
#16
Magdalena Stepien, David J Hughes, Sandra Hybsier, Christina Bamia, Anne Tjønneland, Kim Overvad, Aurélie Affret, Mathilde His, Marie-Christine Boutron-Ruault, Verena Katzke, Tilman Kühn, Krasimira Aleksandrova, Antonia Trichopoulou, Pagona Lagiou, Phlippos Orfanos, Domenico Palli, Sabina Sieri, Rosario Tumino, Fulvio Ricceri, Salvatore Panico, H B As Bueno-de-Mesquita, Petra H Peeters, Elisabete Weiderpass, Cristina Lasheras, Catalina Bonet Bonet, Elena Molina-Portillo, Miren Dorronsoro, José María Huerta, Aurelio Barricarte, Bodil Ohlsson, Klas Sjöberg, Mårten Werner, Dmitry Shungin, Nick Wareham, Kay-Tee Khaw, Ruth C Travis, Heinz Freisling, Amanda J Cross, Lutz Schomburg, Mazda Jenab
BACKGROUND: Copper and zinc are essential micronutrients and cofactors of many enzymatic reactions that may be involved in liver-cancer development. We aimed to assess pre-diagnostic circulating levels of copper, zinc and their ratio (Cu/Zn) in relation to hepatocellular carcinoma (HCC), intrahepatic bile duct (IHBD) and gall bladder and biliary tract (GBTC) cancers. METHODS: A nested case-control study was conducted within the European Prospective Investigation into Cancer and Nutrition cohort...
February 28, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28118609/the-clinical-value-of-lncrna-neat1-in-digestive-system-malignancies-a-comprehensive-investigation-based-on-57-microarray-and-rna-seq-datasets
#17
Dan-Dan Xiong, Zhen-Bo Feng, Wei-Luan Cen, Jing-Jing Zeng, Lu Liang, Rui-Xue Tang, Xiao-Ning Gan, Hai-Wei Liang, Zu-Yun Li, Gang Chen, Dian-Zhong Luo
This comprehensive investigation was performed to evaluate the expression level and potential clinical value of NEAT1 in digestive system malignancies. A total of 57 lncRNA datasets of microarray or RNA-seq and 5 publications were included. The pooled standard mean deviation (SMD) indicated that NEAT1 was down-regulated in esophageal carcinoma (ESCA, SMD = -0.35, 95% CI: -0.5~-0.20, P < 0.0001) and hepatocellular carcinoma (HCC, SMD = -0.47, 95% CI: -0.60~-0.34, P < 0.0001), while in pancreatic cancer (PC), NEAT1 was up-regulated (SMD = 0...
March 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28109714/biliary-tumors-with-pancreatic-counterparts
#18
Yasuni Nakanuma, Yoshiko Sudo
Some biliary diseases mimic pancreatic diseases pathologically as well as pathogenetically. Such diseases can be called "biliary diseases with pancreatic counterparts". Biliary intraepithelial neoplasm (BilIN), intraductal papillary neoplasm of bile ducts (IPNB), hepatobiliary mucinous cystic neoplasm (hMCN), and IgG4-inflammatory pseudotumor represent the biliary counterparts of pancreatic intraepithelial neoplasm (PanIN), intraductal papillary mucinous neoplasm of pancreas (IPMN), pancreatic MCN, and mass forming type 1 autoimmune pancreatitis (AIP), respectively...
December 20, 2016: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/28106928/diagnostic-considerations-for-cholestatic-liver-disease
#19
REVIEW
Galia Pollock, Gerald Y Minuk
Cholestatic liver disease results from insufficient bile synthesis, secretion and/or flow through the biliary tract. Common presenting features include fatigue, pruritus and cholestatic liver enzyme abnormalities wherein elevations of serum alkaline phosphatase and gamma-glutamyltransferases levels exceed those of alanine and aspartate aminotransferases. With prolonged cholestasis, fat soluble vitamin deficiencies, fibrosis, cirrhosis and on occasion, carcinoma of the biliary tract or liver can occur. Once mechanical obstruction to bile flow has been ruled out, the majority of causes can be classified as immune-mediated, infectious or miscellaneous...
January 20, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28094162/intrahepatic-cholangiocarcinoma
#20
Masayuki Nakano, Shun-Ichi Ariizumi, Masakazu Yamamoto
Cholangiocarcinoma, also referred to as cholangiocellular carcinoma (particularly in Japan), develops along the biliary tract. The tumor may be intra- or extrahepatic and have different features with specific treatments based on the site of origin. Guidelines for diagnosis and management of cholangiorcarcinoma, such as those proposed by EASL (European Association for the Study of the Liver)(1) and the Mayo Clinic(2) classify the tumor into intrahepatic, perihilar, and distal cholangiocarcinoma. There are three main macroscopic patterns of growth of cholangiocarcinoma: mass-forming, periductal-infiltrating and intraductal...
January 5, 2017: Seminars in Diagnostic Pathology
keyword
keyword
50186
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"